Líder em edição genética que caiu 92%, pode estar a ser oferecida gratuitamente pelo mercado

Imagine: someone has a genetic disease, and the doctor tells him he needs lifelong medication, costing $470,000 per year, potentially over $5 million in a lifetime. Then a company says: we can give you a shot, permanently edit your genes, and cure you with one dose.

This is not science fiction. The company is called Intellia Therapeutics, which has already achieved in vivo CRISPR gene editing in over 600 patients.$NTLA

Even more surprisingly — the company’s stock price plummeted from $176 in 2021 to today’s $14.78, a 92% drop. Its current market cap is $1.75 billion, minus $600 million in cash, meaning the market values its two Phase 3 clinical pipelines at only $1.15 billion.

And Lilly acquired Verve in 2025 for $1-1.3 billion — a company with only Phase 1b data on in vivo gene editing. Intellia has two Phase 3 trials, yet is only valued at $1.15 billion?

This is a classic crisis investment scenario: a good company facing a reversible crisis × being mispriced by sentiment at an extremely low stock price × market potential with huge growth prospects.

Today I will use my “Growth Company Crisis Investment Research Method” with its 14-dimensional framework to thoroughly analyze NTLA.

1. What exactly is it doing? The dream factory for one-shot cures for genetic diseases

Intellia is the only publicly listed company worldwide that has successfully achieved in vivo CRISPR gene editing in humans. Its technology principle is simple: via intravenous injection, deliver lipid nanoparticles loaded with CRISPR tools into your body, precisely edit disease-causing genes. One injection, permanent effect.

Two core products, two hundred-billion-dollar markets

Nex-z (ATTR amyloidosis): One injection, TTR protein permanently reduced by over 90%, stable without rebound over 36 months of follow-up. 47% of patients improved by ≥1 stage in cardiac function. To compare, current lifelong treatment costs for ATTR patients are $270k–$480k per year, $2.7–4.8 million over 10 years.

Lonvo-z (Hereditary Angioedema, HAE): Even more impressive — 97% of 32 patients experienced complete attack freedom after a single injection, with over 32 months of follow-up. Monthly attack rate dropped by 96%. Previously, HAE patients spent $550k–$680k annually on preventive medication; now one shot solves it.

A simple calculation: if HAE patients use traditional drugs for 20 years, costs exceed $13.6 million. A one-time gene editing priced at $1 million could save over $12.6 million. This is not only a boon for patients but also the core logic for payers and healthcare systems to accept high-priced gene editing.

2. Why is it so cheap? A review of four crises

Understanding why the stock fell from $176 to $14 is the premise for buying. This is not a one-time plunge but a superimposition of four crises:

Crisis ① Biotech sector crash (2021–2024): Rising interest rates + capital outflows, the entire gene editing sector fell 70–90% from peak. CRSP, BEAM, EDIT all hit hard.

Crisis ② Patient death incident (Q4 2025): A patient with ATTR-CM died in the MAGNITUDE trial, causing a single-day stock crash. Although investigation showed the death was unrelated to Nex-z (the patient was high-risk late-stage ATTR-CM), market panic had already set in.

Crisis ③ FDA clinical pause (December 2025): FDA issued clinical hold on MAGNITUDE and MAGNITUDE-2, requiring additional safety data. Stock plunged again to a historic low of $6.73 (intraday).

Crisis ④ Layoffs + pipeline cuts (January 2025): 42% of staff laid off, multiple pipelines including NTLA-3001 cut. Market interpreted as “they’re about to go under.”

But — note this “but” — each of these four crises has already shown signs of positive reversal:

✅ Sector rebound: In Q1 2026, the gene editing sector rebounded overall, Citibank raised target prices to $28.

✅ Death incident clarified: FDA evaluated and confirmed the death was unrelated to treatment.

✅ Clinical pause lifted: On March 2, 2026, FDA fully lifted the clinical hold, MAGNITUDE resumed enrollment. The stock rebounded nearly 4.8% that day.

✅ Layoffs = focus: Cutting non-core pipelines and concentrating all resources on the two most valuable Phase 3 products is a rational strategic contraction.

3. Is it viable? Nobel founder + pharma veteran

CEO John Leonard: Former Chief Scientific Officer at AbbVie, developer of Humira, the world’s best-selling drug. Joined Intellia in 2014 as the first employee recruited, became CEO in 2018. His wife has multiple sclerosis, which fuels his drive to develop new drugs.

Founding team: Jennifer Doudna (2020 Nobel Chemistry laureate, co-inventor of CRISPR), Derrick Rossi (co-founder of Moderna), Rodolphe Barrangou (US National Inventors Hall of Fame), and others—seven top scientists founded the company in 2014.

Most important insider signal: Director Fred Cohen bought 150,000 shares at $9.35/share on January 5, 2026, investing about $1.4 million. A rare large insider open market buy.

4. Competitive landscape: in vivo vs in vitro, a dimensionality reduction

Many compare Casgevy (CRISPR Therapeutics’ product, the first approved CRISPR drug globally) with Intellia — this is a mistake. They are two completely different species:

Casgevy (ex vivo): Requires extracting patient’s stem cells → editing outside the body → chemotherapy to clear marrow → re-infusion. Complex, risky, non-repeatable. In 2025, fewer than 100 infusions total.

Intellia (in vivo): Simple IV injection → direct gene editing inside the body. No hospitalization, no chemotherapy, repeatable. MAGNITUDE alone has treated over 650 patients.

This explains why Lilly paid $1.3 billion to acquire Verve (also in vivo gene editing, but only Phase 1b data), while Intellia with two Phase 3 trials is valued at only $1.75 billion.

5. Cross-validation of ten valuation methods (core conclusion)

This is the part I spend the most time on in my research. Here are the direct conclusions:

Valuation method Valuation result Corresponding stock price

① rNPV (probabilistic net present value) ~$3.77 billion ~$32/share

② Comparable deal (Verve acquisition reference) $2–3 billion $17–25/share

③ Comparable companies (CRSP/BEAM reference) $1.5–1.6 billion ~$13–14/share

④ DCF baseline scenario ~$25–35/share ~$25–35/share

⑤ Book value (hard bottom) $671 million ~$5.69/share

⑥ Market cap / cash ratio Pipeline only priced at $1.15 billion Significantly undervalued

⑦ Per pipeline valuation ~$875 million/pipeline < Verve’s $1–1.3 billion per pipeline

⑧ Replacement cost method ~$3–5 billion ~$25–42/share

⑨ Analyst consensus target price Median $19–22 +30–50% upside

⑩ Historical valuation range ATH $176 / 52-week low $6.73 Current at 92% percentile of ATH

Overall conclusion: NTLA’s reasonable valuation range is $20–35/share (base scenario), with 35–137% upside from today’s $14.78.

Note: analyst target price ranges are extremely dispersed ($5–$106), reflecting NTLA’s core contradiction: if HAELO data succeeds, it’s a $3–5 billion company; if it fails, it’s worth only cash on hand. Market disagreement itself is an opportunity.

6. Short interest 33%: historic short covering potential

NTLA’s short interest accounts for 33% of free float (about 39 million shares), with 7.7–10.8 days to cover. This is an extreme short level.

If HAELO data is positive, considering the over 7-day coverage, a short squeeze could trigger a fierce short covering rally. Short interest has fallen from 44.31 million to 39.44 million shares, indicating some shorts are starting to cover.

Institutional ownership is about 88.6% (315 institutions), with top holders including ARK Investment (Cathie Wood), Vanguard, BlackRock, and Regeneron among the top ten.

7. The most critical catalyst: 2–3 months’ life-or-death decision

This is the core of the entire investment logic:

Catalyst Time Impact

**HAELO Phase 3 unblinding Mid-2026 **Decisive event! Success = BLA submission; failure = major negative

Lonvo-z BLA submission Late 2026 Initiate FDA review process

Q1 2026 earnings report April 30, 2026 Cash update, pipeline progress

Lonvo-z US listing First half 2027 First revenue from product

8. Where are the risks? Three unavoidable pitfalls

① Cash runway tight: $605 million cash, quarterly burn ~$64 million, runway about 18–22 months. If HAELO data is delayed or fails, must raise funds before 2027, causing dilution. Good news: the company has $1.04 billion ATM financing capacity reserved.

② Binary clinical outcomes: HAELO is a binary event — success could double the stock, failure could drop it to $3–$5 cash value. No middle ground.

③ Securities litigation: In February 2025, a class-action lawsuit was filed alleging misleading statements about NTLA-3001. No evidence of actual fraud yet, but ongoing monitoring needed.

9. Conclusion: cautious buy, staggered accumulation

Three questions for building a position:

Are you willing to be a shareholder of this company? Yes. One-shot cure for genetic diseases is one of the most transformative innovations in medical history.

Can you sleep well after buying? Depends on position size. Recommended to keep at 2–5% of total portfolio.

Is there a 10x upside in 5 years? About 5–10% chance; 3–5x (to $45–75) about 25–35%. Still attractive asymmetric return in high-risk biotech investing.

Suggested staged buying plan:

First batch (30% position): Establish a base at current price.

Second batch (40%): Add after positive HAELO data.

Third batch (30%): Complete after BLA submission confirmation.

Stop-loss: If HAELO data underperforms, exit immediately.

The core logic of investing in NTLA boils down to one sentence:

Do you believe that a single injection will truly cure genetic diseases, and that Intellia is the best vehicle to realize this vision? At current prices, the market’s answer is extremely pessimistic. If the market is wrong, the upside will be astonishing.

⚠️: This article is only a personal research sharing and does not constitute any investment advice!